Roy_Chan

Professor Roy Chan explained why sexually-transmitted diseases are managed by dermatologists

Interview with Prof Roy Chan, former Director of the National Skin Centre and Founding President of Action for AIDS (Singapore). He explained why sexually-transmitted diseases are managed by dermatologists in Singapore, and also discussed the state of HIV social acceptance and management in Singapore

ATS-7-web

Vendor – Call for Expression of Interest

AFA – Anonymous Client Testing Support (ACTS)

Expression of Interest – Clinic information system


Expressions of Interest are requested from health IT software vendors or developers to provide the first stage of a system to computerise the documentation and workflow of the Anonymous Testing Service. The ATS is one of the testing and support services offered by Action For Aids Singapore, a charity focused on prevention of HIV infection.

The overall scope of the project and scope of this first stage is defined in documentation to be provided on completion of the mutual NDA. An acceptable NDA is attached. AFA will consider accepting any suitable alternative format provided by the prospective vendor, highlighting in clear English all differences between it and the sample form. It is anticipated that phase 1 will be completed by end of August 2015.


 

The expression of interest process will consist of:

 

 

  1. A maximum 5 page document outlining the scope of the solution and a high level design approach and addressing issues outlined in the documents provided, including if needed hardware requirements, timelines and ability for completion of the additional elements of the solution, IP and escrow arrangements, and 3 relevant client references with contact details. Screen captures and architectural diagrams may be added within reason to the application in addition to the 5 pages.
  2. A separate costing estimate covering hardware (if relevant), software, integration, implementation support and adjustments following implementation and support for the initial 12 months of operation.
  3. A separate Statement about approach to provision of a product demonstration. Ability to access example test systems to provide an overview of functionality and capability would be appreciated, at either the initial evaluation or short list stage.

A short list of vendors will be requested to provide:

  1. Demonstration of the development platform providing a demonstration implementation of a few relevant portions of the main pre-testing data collection form (see attachment A), application of a decision support rule to guide the test selection decision, workflow, and production of report in excel format.
  2. Demonstration of previously developed software applications if possible.
  3. A detailed costed proposal for stage 1 with estimated effort for delivering other components subsequently.

It is anticipated that demonstrations and interviews will be conducted remotely using GoToMeeting or similar platform.

Provision of additional tender documentation will be provided on receipt of the attached Non-disclosure agreement, binding on both parties. A confidential tender briefing and question session will be held by teleconference at a date to be agreed.

The closing date for electronic submission of EOI will be 20/07/2015

Please return the NDA electronically (signed and scanned) to

Ms Norani Othman Tel +65 6254 0212 norani@afa.org.sg

Example of AFA client registration and data collection form is attached as an excel spreadsheet.

 

N Sarita Shah presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

XDR-TB spread person-to-person, not by failure of drug

XDR-TB spread person-to-person, not by failure of drug treatment


First published on http://www.aidsmap.com/ on 26 Feb 2015


Keith Alcorn

N Sarita Shah presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

The vast majority of people with extensively drug-resistant tuberculosis (XDR-TB) diagnosed in the world’s most extensive outbreak have acquired their infection from another person, not as the result of the failure of treatment for multidrug-resistant strains of tuberculosis (MDR-TB), N Sarita Shah told the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, on Wednesday.

Read more

Jared Baeten presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

PrEP and ART could almost eliminate HIV infection

Combining PrEP and ART could almost eliminate HIV infection, east African study finds


First published on http://www.aidsmap.com/ on 26 Feb 2015


Gus Cairns
Jared Baeten presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Jared Baeten presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Giving both pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) to heterosexual couples where one partner has HIV (serodiscordant couples) can almost eliminate the chance of infection in the HIV-negative partner, a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, yesterday has shown.

This study was a first in a number of ways. It is the first to combine the ideas of PrEP and of ‘treatment as prevention’ in a systematic and sequenced way. It is the first large study in Africa to use a ‘risk score’ specifically to target the intervention to those most at risk of HIV. And it is the first study of treatment as prevention to document near-elimination of HIV transmission not just from the HIV-positive partner in a serodiscordant couple, but also from extramarital partners. Read more

ChristineDanel_1000_707

Early HIV treatment reduces risk of serious illness and death by 44%

Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows


First published on http://www.aidsmap.com/ on 26 Feb 2015


Keith Alcorn

Christine Danel presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Starting HIV treatment at a CD4 cell count above 500 reduced the risk of serious illness including tuberculosis (TB), and death, by 44% when compared to starting treatment according to World Health Organization (WHO) guidelines, results from the seven-year Temprano study show. The findings were presented on Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA.

Read more

youtube

AfA Look Back 2014

As the year draw to a close, we would like to take this chance to look back on a wonderful year, filled with activities, sweat and joy.

So here’s a huge thank you to all our volunteers, members and advocates. We couldn’t have done it without you. Let’s do it (even) better in 2015.

—————

Song – Broke for Free – Night Owl http://freemusicarchive.org/music/Broke_For_Free/Directionless_EP/

Non-Occupational Post-Exposure HIV Prophylaxis

Introduction to PEP

Post-Exposure Prophylaxis (PEP) is any prophylactic (preventive) treatment started immediately after exposure to be pathogen (such as a virus) with the aim to prevent infection.


What is PEP?

PEP is the use of Antiretroviral Therapy (ART), often becoming the standard of care for healthcare workers, who hold on to the risk of occupational exposure to HIV. PEP should ideally be initiated within 72 hours of exposure, failing which is not advised.


Who needs PEP?

Anyone who have experienced condom failure or were involved in any form of unprotected anal or vaginal intercourse, receptive fellatio with ejaculation with:

  • A known HIV-infected partner and or
  • HIV at-risk groups (commercial sex workers, IV drug users, men who have sex with men – including bisexual men) and or
  • A person who was forced into any sexual act involuntarily (raped).

Before PEP Prescription

A detailed history of the exposure if crucial in evaluating a patient. An assessment will then be done by the doctor to determine the likelihood of HIV transmission. The level of risk can be estimated with the following table:

ExposureEstimated Risk
Needle stick injury0.33%
Receptive anal intercourse1%
Insertive anal intercourse0.04%
Receptive vaginal intercource0.1%
Insertive vaginal intercourse0.05%
Receptive fellatio with ejaculation (Oral Sex)0.04%
Sharing needles0.67%

The patient will then be advised on the risks, benefits and alternatives of PEP. Should the decision be made to proceed with treatment, it would be important to follow-up for: potential side effects of the medications, repeat HIV screenings as well as reinforcement of counselling messages.


Course of PEP

The full course for this PEP drug combination will be for a duration of 28 days. AfA Is working closing with DSC Clinic to bring you PEP at very affordable rates.


Adverse Effects of PEP

Any drugs prescribed have the potential possibility of side effects.

These symptoms includes nausea and diarrhoea.

It is advisable to check with your healthcare provider on what are the possible side effects on the medications being prescribed to you.


Do you think you need PEP?


Other Information

  • Exposure to saliva, urine, tears and sweat are not thought to be infectious
  • HIV transmission from splashes of contaminated fluids to mucosal surface (i.e. nostrils, mouth, lips, eyelids, ears, genital area and the anus) or non-intact skin is likely to be low, although it has not been accurately justified
  • PEP treatment is not 100% effective, best reports quote that PEP can potentially decrease the possibility of transmission by 81%